Prof. Anthony Chan

Chief Director

• Conducted >80 clinical trials since 2000 with 10 Phase 1 studies
• Led pivotal studies in setting new treatment standard in multimodality approaches in nasopharynx cancer
• Developed the clinical application of the biomarker EBV DNA and pioneered immunotherapeutic and targeted therapeutics in nasopharynx cancer
• Published over 270 peer-reviewed papers, 49 book chapters and reviews, and delivered over 160 international lectures
• Served on the Editorial Board of Journal of Clinical Oncology and is currently Associate Editor of Annals of Oncology

Prof. Brian Tomlinson

Consultant (honorary)

(Clinical Pharmacology)

• Investigator in Phase 1 clinical trials, including first-in-man studies, for over 30 years in London and Hong Kong
• Conducted over 20 Phase 1 and over 80 bioequivalence studies in Hong Kong since 1999
• Investigator in numerous Phase 3 clinical trials in lipid disorders, hypertension and diabetes
• Research interest in pharmacogenomics, ethnic differences in drug responses, lipid disorders, hypertension and diabetes

Prof. Brigette Ma

Medical Director

(Oncology)

• PI/ Co-I of over 70 phase I-II-III clinical trials in oncology. Published over 120 peer-reviewed papers and three book chapters on subjects including head and neck cancers, colorectal cancer and phase I clinical research.
• Served on numerous advisory boards of major pharmaceutical companies
• Professor, Honorary Consultant, Medical Director of the Phase I Clinical Trial Centre (Oncology) and Co-Director of the Cancer Drug Testing Unit at Department of Clinical Oncology, CUHK
• Member of the Joint Scientific Committee for Phase 1 Clinical Trials, Centre of Health Protection, Hong Kong Hospital Authority
• Chairman of Phase 1 Clinical Trials Review Panel of Joint CUHK-NTEC Clinical Research Ethics Committee
• Served as Vice-President of the Hong Kong Nasopharyngeal Cancer Study Group, President of the Hong Kong Head and Neck Society, Member of European Society of Medical Oncology (ESMO) Consensus Working Group for metastatic colorectal cancer, Committee member of the WICR for AACR (Women in Cancer Research, American Association of Cancer Research)

Prof. Andrea Luk

Medical Director

(Non- Oncology)

• Extensive clinical trial experience since 2005
• Conducted over 70 clinical trials from Phase 1 to Phase 3
• A specialist in Endocrinology and Internal Medicine
• Research interest in the area of translational research, genomic and epidemiology related to cardiovascular and metabolic diseases

Dr. Herbert Loong

Deputy Medical Director

(Oncology)

• Conducted over 50 oncology phase I-II-III clinical trials in either a PI/Co-I capacity
• International and local experience of conducting phase 1 clinical trials, including completing a Drug Development Fellowship (Phase 1 Clinical Trials) at the Princess Margaret Cancer Centre, University of Toronto (Supervisor: Dr. Lillian Siu)
• Clinical interests in sarcoma medical oncology, neuro-oncology, thoracic oncology and experimental therapeutics (phase 1 clinical trials)
• Convener of the Adult Sarcoma Multidisciplinary Team, Prince of Wales Hospital / The Chinese University of Hong Kong and Honorary Member, Otto Wong Brain Tumour Centre, The Chinese University of Hong Kong

Dr. Risa Ozaki

Deputy Medical Director

(Non- Oncology)

• Conducted close to 100 pharmaceutical sponsored multicentre international trials in all phases ranging from phase 1 to phase 4 studies as well as in investigator initiated studies
• Accrued more than 15 years of experience in pharmaceutical clinical trials as both Principal Investigator and Co-Investigator
• Pharmaceutical studies conducted under the leadership of Dr. Ozaki have been recognized as the top recruiting site
• Rich experience in numerous internal and external audits
• Experienced in regulatory inspections including NMPA inspection with NMPA accreditation obtained for Endocrinology and Phase 1 clinical trial units as NMPA sites at the Prince of Wales Hospital

Dr. Elaine Chow

Deputy Medical Director

(Non- Oncology, Clamp Studies)

• 7 years’ of experience in clinical trials overall including Phase I-IV and BABE studies
• 7 years’ experience of euglycaemic, hypoglycaemic and hyperglycaemic clamp studies in type 1, type 2 diabetes patients and nondiabetic volunteers
• Expertise in continuous glucose monitoring devices (with in-clinic evaluation against YSI) in type 1, type 2 diabetes and chronic kidney disease patients
• Special interest in pharmacokinetics and pharmacodynamics of insulin analogues